Background: To improve the prognosis of patients with pancreatic cancer, more accurate serum diagnostic methods are required. We used serum metabolomics as a diagnostic method for pancreatic cancer.
Introduction
Pancreatic cancer is characterized by rapid tumor progression and early metastasis, and is one of the leading causes of cancer-related death. Pancreatic cancer is considered to be a lethal solid tumor, and its 5-year survival rate is less than 5%. Although the only curative treatment for pancreatic cancer is surgical resection, more than 80% of patients with pancreatic cancer have a locally advanced or metastatic tumor that is unresectable at the time of diagnosis (1) (2) (3) . The clinical symptoms of pancreatic cancer are usually unremarkable until the cancer has progressed to an advanced stage. Furthermore, there is no effective method for its early detection. CA19-9, which is usually used as a tumor marker, is unsuitable for the early detection of pancreatic cancer due to the low sensitivity for resectable stages of disease. In addition, its levels are also increased in other gastrointestinal malignancies and benign pancreaticobiliary diseases such as pancreatitis and cholangitis (4) . Imaging examinations are not costeffective and cannot discriminate pancreatic cancer from benign pancreatic diseases such as tumor-forming pancreatitis. Moreover, exposure to radiation during unnecessary repeated computed tomography (CT) scans might also increase the risk of malignancy (5) (6) (7) . Endoscopic examinations are not appropriate for screening because of their low throughput and the high risk of complications. Therefore, a novel screening and diagnostic method for pancreatic cancer is required. Screening tests for the general population have to be accurate, safe, and convenient, as well as capable of high throughput. Many researchers have devoted considerable effort to discovering biomarkers of pancreatic cancer (8) (9) (10) , and CA242 (11), M2-pyruvate kinase (12) , PBF-4 (13), MIC-1 (14) , PNA-binding glycoprotein (15) , hTert (16) , MMP-2 (17) , and synuclein-g (18) have been reported as candidate biomarkers, but they were not clinically superior to CA19-9 or other clinical examinations.
We have showed the use of metabolomics for diagnosing and evaluating the pathologic conditions of various diseases (19) (20) (21) (22) (23) (24) . Metabolomics is the comprehensive study of low molecular weight metabolites, which are the endpoint of the omics cascade and hence are the closest point in the cascade to the phenotype. The metabolome represents the metabolic profile of a cell, tissue, organ, or organism. Changes in metabolism result in alterations in the abundance of metabolites, and elucidating the metabolomic changes that occur in a particular disease will increase our understanding of it. Therefore, metabolomics has recently developed rapidly in the medical field (25) . Capillary electrophoresis mass spectrometry (CE/MS)-based metabolomic analysis of gastrointestinal cancer tissue revealed that the nutritional conditions in the cancer microenvironment are quite different from those in normal tissue (26) . Regarding the pancreas, we previously found that human serum metabolomics using gas chromatography/mass spectrometry (GC/MS) is able to discriminate patients with pancreatic cancer from healthy volunteers (20) . Similar results were obtained from the nuclear magnetic resonance (NMR)-based metabolic profiling of rat tissues (27) and NMR-based serum metabolomics in humans (28) . In this study, we constructed a diagnostic model for pancreatic cancer using GC/MSbased human serum metabolomics and then confirmed its diagnostic performance via validation analysis and comparisons with conventional tumor markers.
Materials and Methods

Subjects
This study was approved by the ethics committee at Kobe University Graduate School of Medicine (Hyogo, Japan) and conducted between Feb 2009 and Feb 2012. The human samples were used in accordance with the guidelines of Kobe University Hospital, and written informed consent was obtained from all subjects. The serum samples from the patients with pancreatic cancer and the chronic pancreatitis were collected at Kobe University Hospital and another institution. The patients with pancreatic cancer and chronic pancreatitis were clinically or pathologically diagnosed by physicians, radiologists, and/or pathologists. The 6th edition of the Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) classification was used to diagnose pancreatic cancer. The serum samples from the healthy volunteers were obtained from Kobe University Hospital and other institutions. No clinical abnormalities were detected in the healthy volunteers during medical check-ups involving physical, blood, urine, imaging, and/or endoscopic examinations. Medical information, that is, height, weight, history of diseases, history of smoking and drinking, histologic findings, and blood biochemical findings, that is, albumin, total cholesterol, triglyceride, aspartate aminotransferase, alanine aminotransferase, bilirubin, and amylase, of the subjects were obtained from the clinical records and the reports of medical check-ups on the time of registration (Supplementary Tables S1 and S2 ).
Serum samples and preparation
All serum samples were prepared from blood samples collected in the morning using the standard venous blood sampling protocol. The collected blood was centrifuged at 3,000 Â g for 10 minutes at 4 C, and the serum was transferred to a clean tube and stored at À80 C until use. The extraction of low molecular weight metabolites was done according to the method described in our previous report (24) . Oximation and the subsequent derivatization for the GC/MS analysis were also carried out according to the methods described in our previous report (24) . The resultant solution was subjected to GC/MS measurement, as described later.
GC/MS procedure
According to the method described in a previous report (29) , the GC/MS analysis was done using a GCMS-QP2010 Ultra (Shimadzu Co.) with a fused silica capillary column (CP-SIL 8 CB low bleed/MS; inner diameter: 30 m Â 0.25 mm, film thickness: 0.25 mm; Agilent Co.). The front inlet temperature was 230 C. The flow rate of helium gas through the column was 39.0 cm/sec. The column temperature was held at 80 C for 2 minutes and then raised by 15 C/min to 330 C and held there for 6 minutes. The transfer line and ion-source temperatures were 250 and 200 C, respectively. Twenty scans per second were recorded over the mass range 85 to 500 m/z using the Advanced Scanning Speed Protocol (ASSP; Shimadzu Co.).
Data processing was done according to the methods described in previous reports (29, 30) . Briefly, the MS data were exported in netCDF format. The peak detection and alignment were done using the MetAlign software (Wageningen UR). The resultant data were exported in CSV format and then analyzed with in-house analytical software (AIoutput) and an in-house metabolite library for peak identification and semiquantitative analysis. For the semiquantitative analysis, the peak height of each ion was calculated and normalized to the peak height of 2-isopropylmalic acid as an internal standard. Names were assigned to each metabolite peak based on the method of a previous report (30) . All data obtained from the serum samples were simultaneously analyzed using the MetAlign software because it was necessary to ensure that the alignment conditions were the same throughout the data analysis. In the GC/MS analysis, multiple peaks were sometimes detected for a particular metabolite because of TMS derivatization, the presence of isomeric forms, etc. In such cases, the peak that most reflected the level of the metabolite was adopted for the semiquantitative evaluation. Furthermore, the metabolites with relative standard deviation (RSD)% values of more than 20% and those that were mainly derived from the experimental background were not subjected to the semiquantitative evaluation (Supplementary Table S3 ).
Statistical analysis
The pancreatic cancer were randomly allocated to the training set or the validation set study of pancreatic cancer. The healthy volunteers were recruited as age-and sex-matched controls for the pancreatic cancer and were randomly allocated to the training set or the validation set. All of the chronic pancreatitis were included in the validation set study to allow us to evaluate whether our model can be used to discriminate cancer from nonmalignant chronic inflammation. In the training set study, the levels of serum metabolites were compared between the pancreatic cancer and healthy volunteers using the Wilcoxon's rank sum test. The metabolites selected via the stepwise method were subjected to multiple logistic regression analysis to construct a diagnostic model. The multicolinearity of the selected variables was assessed by calculating their variance inflation factors (VIF). Receiver operating characteristic (ROC) analysis was used to calculate area under the ROC curve (AUC), sensitivity, and specificity values for the model to evaluate its diagnostic performance. The optimal cut-off value of the model was determined from its ROC curve. In the validation set study, the diagnostic model was evaluated using the AUC, sensitivity, specificity, and accuracy values observed at the cut-off value obtained in the training set study. In addition, to evaluate the serum metabolic changes in chronic pancreatitis, another set of healthy volunteers was prepared as age-and sex-matched controls for the chronic pancreatitis. The levels of serum metabolites were compared between the chronic pancreatitis and healthy volunteers using the Wilcoxon's rank sum test. In all cases, P values of less than 0.05 were considered to indicate a significant difference. These analyses were done using the default conditions of JMP9 (SAS Institute Inc.).
Results
The clinical characteristics of the patients and healthy volunteers are shown in Tables 1 and 2 , and the additional information of the study subjects were exhibited in Supplementary Tables S1 and S2. Using our GC/MS-based metabolomics approach, which mainly targeted watersoluble metabolites, 159 compounds were detected in the subjects' sera (Supplementary Table S3 ). Among them, 2-isopropylmalic acid was used as an internal standard, and 113 metabolites were excluded because of their instability, contaminants, and so on as described earlier. Therefore, the remaining 45 metabolites were subjected to semiquantitative evaluation. In the training set study, 18 of these metabolites displayed significantly altered levels in the pancreatic cancer compared with the healthy volunteers Table 3 ). The AUC, sensitivity, and specificity of these 18 metabolites were calculated to evaluate their diagnostic performance as individual biomarkers of pancreatic cancer (Supplementary Table S4 ). 1,5-Anhydo-D-glucitol displayed the highest AUC value as an individual biomarker (0.83499), and its sensitivity and specificity values were 86.0% and 71.4%, respectively. There were no metabolites whose sensitivity and specificity values were both over 80%.
To construct a more effective diagnostic model for pancreatic cancer, we conducted multivariate analysis using the results from the training set study. First, 4 metabolites were selected from the 45 metabolites listed in Table 3 via the stepwise method; that is, xylitol, 1,5-anhydro-D-glucitol, histidine, and inositol. Using these metabolites, which did not display multicolinearity (Supplementary Table S5 ), a diagnostic model for pancreatic cancer was established using multiple logistic regression analysis (Supplementary Table S6 ). The diagnostic model produced using these 4 independent variables was as follows: In the training set study, this model displayed an AUC value of 0.92857 (Fig. 1) , and the optimal cut-off value was 0.5137. At this cut-off value, the model's sensitivity and specificity values were 86.0% and 88.1%, respectively. In contrast, the sensitivity and specificity of CA19-9 were 62.8% and 100%, respectively, and those of CEA were 44.2% and 97.6%, respectively ( Table 4 ). The healthy volunteers had their serum CA19-9 and CEA levels measured during health checks, and healthy volunteers whose serum CA19-9 and CEA levels were higher than the relevant clinical cut-off value were excluded from the study. Therefore, the specificity of these conventional tumor markers was markedly high.
The ROC curves for these diagnostic methods obtained in the validation set study are shown in Fig. 2 . The AUC of the model was 0.76004. At this cut-off value, its sensitivity and specificity values were 71.4% and 78.1%, respectively.
In the validation set, the AUC, sensitivity, and specificity of CA19-9 were 0.79762, 69.0%, and 85.9%, respectively, whereas those of CEA were 0.66488, 35.7%, and 79.7%, respectively ( Fig. 2 and Table 4 ). Furthermore, in the validation set study, the sensitivities of our model, CA19-9, and CEA in resectable pancreatic cancer (stages 0 to IIB) were 77.8%, 55.6%, and 44.4%, respectively. In the case of chronic pancreatitis, their false-positive rates were 17.4%, 30.4%, and 43.5%, respectively ( Table 4 ). The scatter plots of the predictive values obtained from these diagnostic methods in all 191 cases are shown in Supplementary Fig. S1 . The accuracy values of the conventional tumor markers increased with cancer progression, especially in stages III and IV disease. On the contrary, our model even displayed a high accuracy level in the early stage pancreatic cancer cases.
We also conducted comparisons between the chronic pancreatitis and healthy volunteers to assess the influence of nonmalignant chronic inflammation on the serum metabolome. The subject information for this evaluation is shown in Table 2 and Supplementary Table S2 . As a result, 16 metabolites were found to display significantly altered levels in chronic pancreatitis, as shown in Supplementary Table S7 .
Discussion
Recently, the possibility of using metabolomics as a diagnostic tool for pancreatic cancer has been investigated in a number of studies (20, 27, 28, (31) (32) (33) (34) . However, in these reports, principle component analysis (PCA) was used to test the use of metabolomics. PCA cannot be used as a diagnostic method for evaluating individual clinical samples because it requires all samples in a data set to be analyzed simultaneously. Thus, a practical clinical diagnostic tool for pancreatic cancer needs to be developed and evaluated by calculating its sensitivity and specificity using an independent sample set. Therefore, we first constructed and then validated a diagnostic model via the stepwise variable selection method and subsequent multiple logistic regression analysis. All of the metabolites measured in our system are present in a variety of the body's parts including blood in living organisms and are not specific to cancer; hence, they are not suitable as individual biomarkers of specific diseases. Therefore, to develop effective biomarkers several metabolites were combined to produce a multi-biomarker model using multiple logistic regression analysis. Furthermore, to discover reliable biomarkers, well-verified and controlled serum samples were collected from multiple institutions, and then we conducted measurements and data analyses using stringent bioinformatics methods.
Regarding pancreatic disease, there are 3 major problems in the clinical field. The first is the difficulty of detecting pancreatic cancer early in resectable stages. In this study, we confirmed the use of our serum metabolomics-based diagnostic model for detecting resectable pancreatic cancer; that is, the sensitivity of this model for one of the major risk factors for pancreatic cancer. Many gastroenterologists follow-up chronic pancreatitis with scheduled CT, magnetic resonance imaging (MRI), and endoscopic ultrasound scans (EUS); tumor marker tests; and endoscopic retrograde cholangiopancreatography (ERCP), but the initial malignant changes are frequently overlooked, and pancreatic tumors can rapidly become unresectable. In addition, unnecessary resections for benign inflammatory lesions are sometimes done because of false-positive results from CA19-9 and/or imaging examinations. In this study, our metabolomics-based diagnostic model even showed the lower false-positive rate than CA19-9 in chronic pancreatitis (Table 4) , indicating that using it could reduce the incidences of missed malignant changes in chronic pancreatitis and unnecessary major surgery for benign inflammatory lesions. The third clinical problem is the risk of complications during pancreatic examinations. In our metabolomic analysis, serum samples were used as the experimental materials. The samples were taken according to a standard venous blood sampling method. The risk of complications in this procedure was quite low, and its throughput was relatively high. Therefore, our metabolomic approach is acceptable as a screening method for large populations.
Jiang and colleagues suggested tumor-specific growth factor (TSGF) as a candidate serum biomarker for pancreatic cancer and found that it displayed 91.6% sensitivity and 83% specificity (35) . However, its sensitivity for stages I and II pancreatic cancer was decreased to 60.0% and 75.0%, respectively. CA242 was showed to be a biomarker candidate for pancreatic cancer by the same group and Kawa and colleagues, but it suffered from the same problem; that is, it displayed low sensitivity for resectable disease (11). Koopmann and colleagues Diagnostic model CA19-9 CEA Figure 1 . The ROC curve of the diagnostic model and the tumor markers in the training set study. The AUC of the ROC curve, cut-off value, sensitivity, and specificity of each diagnostic method are summarized in Table 4 . (Table 4 ). In addition, the serum metabolites selected as variables in our diagnostic model did not display the significant inter-day and intra-day variances in our previous report (20) . This superiority will provide a substantial benefit in clinical use. The pathogenesis of pancreatic disease causes significant decreases in the serum levels of amino acids and fatty acids in pancreatic cancer (valine, n-caprylic acid, threonine, nonanoic acid, methionine, asparagine, glutamine, lysine, histidine, and tyrosine) and chronic pancreatitis (valine, proline, methionine, lauric acid, asparagine, glutamine, and tyrosine). Other research groups have showed similar decreases in plasma samples from pancreatic cancer and chronic pancreatitis using high-performance liquid chromatography (HPLC) analysis (40) . It is well known that the uptake and catabolism of amino acids and fatty acids are enhanced to support rapid cell proliferation in cancer tissues (41) , and these decreases may be explained as a result of the enhanced usage in tumors. Patients with pancreatic disease are also troubled by malnutrition because of pancreatic endocrine and exocrine insufficiency. Therefore, there is a possibility that the decreases in their serum metabolite levels also reflect malnutrition. In this study, a reduction in the serum level of 1,5-anhydro-D-glucitol was observed in the pancreatic cancer (Table 3) . 1,5-Anhydro-D-glucitol is a serum biomarker of short-term glycemic control (41), and the decreased serum level of 1,5-anhydro-D-glucitol means the presence of hyperglycemia and glycosuria of the past few days. These results suggest that glucose tolerance was impaired in these patients because of pancreatic insufficiency. On the basis of our findings, the serum metabolome seems to reflect not only metabolic changes in focal lesions but also the systemic responses to these pancreatic diseases. However, it is necessary to elucidate the reasons for these alterations in the serum metabolome.
Regarding our study design, there are some limitations. First, other cancers and chronic diseases as auto immune pancreatitis or tumor forming pancreatitis should be included into the study groups to evaluate the specificity more strictly. The sample size, especially in resectable pancreatic cancer, was not also enough to conduct stringent subgroup analyses. Second, there is a possibility that potential biases and insufficient study size of this study might raise the false significant results. To overcome these problems, development of rigorous standard method and quality control procedures for the biomarker study are needed strongly, and for example Pepe and colleagues proposed that the prospectivespecimen-collection and retrospective-blinded-evaluation (PRoBE) design is considered as the standard method to discover and evaluate the biomarkers for screening or diagnosis (42) .
In conclusion, we developed a serum metabolomicsbased diagnostic model for pancreatic cancer using multiple logistic regression analysis. Our model possessed higher accuracy than conventional tumor markers especially at detecting the patients with resectable pancreatic The ROC curves of the diagnostic model and tumor markers in the validation set study. The AUC of the ROC curve, cut-off value, sensitivity, specificity, and false-positive rate of each diagnostic method are summarized in Table 4 .
cancer in cohort including the patients with chronic pancreatitis. Although the increased number of well-defined samples including various diseases and the large-scale multicenter study are still necessary for strict evaluation of specificity and for construction of the robust reliable model, this novel diagnostic approach is expected to improve the prognosis of patients with pancreatic cancer by detecting their cancer early, when it is still in a resectable and curable state.
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